Medicilon Appoints Dr. Lilly Xu as New Chief Technology Officer

Medicilon Welcomes Dr. Lilly Xu as Technical Director

Medicilon, a leading contract research organization (CRO) specializing in preclinical research, has appointed Dr. Lilly Xu as its new Chief Technology Officer (CTO). This strategic move, announced on January 2, 2025, comes as Medicilon aims to enhance its technological capabilities and expand its global footprint.

Dr. Xu brings more than 30 years of extensive experience in the realm of drug development and innovation. Her deep expertise spans various aspects, including pharmacokinetics, toxicology, and drug metabolism, making her a significant asset to Medicilon. Throughout her career, Dr. Xu has successfully led numerous global drug development programs, ranging from early-stage discoveries to clinical trials. Furthermore, she has held prominent positions in several major pharmaceutical and biotechnology firms, such as Pharmaron, Icagen, Purdue Pharma, Sanofi, and Amgen.

According to Dr. Chunlin Chen, Founder and CEO of Medicilon, "We are thrilled to welcome Dr. Xu at this pivotal stage of Medicilon’s development. Her profound experience and global perspective align perfectly with our vision of fostering innovation and broadening our international presence." This endorsement highlights the high expectations placed on Dr. Xu to propel Medicilon forward in a competitive industry.

In her own words, Dr. Xu expressed her enthusiasm about joining Medicilon’s forward-thinking team, saying, "It is a great honor for me to join Medicilon. I look forward to contributing to innovative developmental platforms that accelerate the transformation of scientific research into clinical breakthroughs, achieving milestones that benefit our global clients and their patients."

Medicilon is continually enhancing its advanced research platforms, focusing on nucleic acids, antibody-drug conjugates (ADCs), PROTACs, cell and gene therapy, maintaining its position as a leader in preclinical drug development.

This appointment is expected to bolster Medicilon's capability in delivering cutting-edge research solutions, ultimately aiding in the great pursuit of novel therapies and medications that can change lives.

For more details about Medicilon and their offerings, visit their official website at https://www.medicilon.com/.

For media inquiries, please refer to the image link: Dr. Lilly Xu